Moreover, suppression of KLF5-VEGFA axis by the inhibitors of upstream oncogenic signaling pathways (such as RTKs and PI3K) and inhibitor of KLF5 suggested KLF5 as a potential therapeutic target in bladder cancer. This evidence concerns the gene VEGFA and urinary bladder carcinoma.